Edwards Declares Victory In CardiAQ Lawsuit Vs Neovasc
This article was originally published in Clinica
Executive Summary
A jury in Boston has recommended that Neovasc pay CardiAQ, now part of Edwards Lifesciences, $70m in damages to resolve a two-year old intellectual property lawsuit, Edwards announced May 19.